We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
- Authors
Di Lorenzo, Giuseppe; Ferro, Matteo; Buonerba, Carlo
- Abstract
Sipuleucel-T is known to be very well tolerated and to prolong overall survival, but not progression-free survival, measured according to prostate-specific antigen variations and radiographic progression. Its exact mechanism is unknown. Although the article does not present new data, a new way of assessing immunotherapy efficacy is proposed. This involves measuring 'consecutive' times to progression, in an attempt to capture the delayed effects of immunotherapy.
- Publication
BJU international, 2012, Vol 110, Issue 2 Pt 2, pE99
- ISSN
1464-410X
- Publication type
Journal Article
- DOI
10.1111/j.1464-410X.2011.10790.x